— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.
— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected
— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Micron Technology Inc. (NASDAQ: MU) reported third quarter 2022 earnings results today. Revenue increased 16% year-over-year to $8.64 billion. GAAP net income was $2.63 billion, or $2.34 per share, compared
Shares of Constellation Brands Inc. (NYSE: STZ) were down 4% on Thursday despite the company beating expectations on its first quarter 2023 earnings results. The stock has dropped 7% year-to-date.
Constellation Brands, Inc. (NYSE: STZ) reported first quarter 2023 earnings results today. Net sales increased 17% year-over-year to $2.3 billion. Net income attributable to CBI was $390 million, or $2.06